XML 71 R55.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Sep. 30, 2018 | Oct. 01, 2017 | Sep. 30, 2018 | Oct. 01, 2017 | Dec. 31, 2017
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change in Operating Income Loss | (7.70%) |  | (1.60%) |  |
In process research and development charge | $ 9,228 |  | $ 9,228 |  | $ 11,283
Earnings before provision for taxes on income | 4,423 | $ 4,790 | 14,877 | $ 15,113 |
Restructuring charges | 88 | 69 | 187 | 165 |
Asset Impairment Charges |  |  | 1,226 | 309 |
PHARMACEUTICAL |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Royalty monetization |  |  |  | 200 |
Litigation expense |  |  |  | 100 |
Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Restructuring charges | 200 | 200 | 400 | 500 |
Litigation expense |  | 100 | 700 | 500 |
Asset Impairment Charges |  |  |  | 200 |
Operating Segments |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income | $ 4,653 | 5,118 | $ 15,722 | 16,004 |
Percentage Change in Operating Income Loss | (9.10%) |  | (1.80%) |  |
Operating Segments | CONSUMER |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income | $ 510 | 878 | $ 1,887 | 2,132 |
Percentage Change in Operating Income Loss | (41.90%) |  | (11.50%) |  |
Amortization | $ 100 | 100 | $ 200 | 200 |
Operating Segments | PHARMACEUTICAL |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income | $ 2,876 | 2,857 | $ 10,193 | 9,934 |
Percentage Change in Operating Income Loss | 0.70% |  | 2.60% |  |
Amortization | $ 700 | 700 | $ 2,300 | 900 |
Acquisition related costs |  | 400 |  |  |
Gain on sale of equity investments |  |  |  | 300 |
Operating Segments | Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income | $ 1,267 | 1,383 | $ 3,642 | 3,938 |
Percentage Change in Operating Income Loss | (8.40%) |  | (7.50%) |  |
Amortization | $ 300 | 300 | $ 800 | 800 |
Corporate, Non-Segment |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Total Segment Operating Income | 230 | 328 | 845 | 891 |
XO1 |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Contingent liability reversal | (200) |  | (200) |  |
Actelion |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Acquisition related costs |  |  | 200 |  |
Actelion | PHARMACEUTICAL |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Acquisition related costs |  |  | 200 | 600 |
NIZORAL | Operating Segments | CONSUMER |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Gain from divestiture | 300 |  | 300 |  |
Compeed | Operating Segments | CONSUMER |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Gain from divestiture |  | $ 400 |  | $ 400 |
PANCREASE | Operating Segments | PHARMACEUTICAL |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Gain from divestiture | 100 |  | 100 |  |
Purchased In-Process Research And Development |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
In process research and development charge | 2,226 |  | 2,226 |  | $ 4,201
Purchased In-Process Research And Development | Alios Biopharma Inc and XO1 Limited |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
In process research and development charge | $ 1,100 |  | $ 1,100 |  |

X
- Definition Percentage change in operating income loss. + References No definition available. + Details
Name: | jnj_PercentageChangeInOperatingIncomeLoss
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Revenue, Monetization of Royalty + References No definition available. + Details
Name: | jnj_RoyaltyRevenueMonetizationofRoyalty
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_AdjustmentForAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2443-110228 + Details
Name: | us-gaap_GainLossOnDispositionOfAssets1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.13(h)) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 + Details
Name: | us-gaap_GainLossOnSaleOfEquityInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747 + Details
Name: | us-gaap_RestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_XO1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_NIZORALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_CompeedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_PANCREASEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AliosBiopharmaIncandXO1LimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |